Method of treatment of cns disorders

Abstract

The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.

1 . A method of treatment of a central nervous system disorder in a mammalian subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical agent exhibiting combined μ-opioid agonistic activity and at least one of a noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory activity. 
     
     
         2 . The method of  claim 1 , wherein said CNS disorder is selected from a major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, autism, aggression, intermittent explosive disorder, attachment disorder, attention deficit hyperactivity disorder and schizophrenia. 
     
     
         3 . The method of  claim 1 , wherein said pharmaceutical agent exhibits combined μ-opioid agonistic activity, and a noradrenergic, serotonergic and dopaminergic reuptake transporter inhibitory activity. 
     
     
         4 . The method of  claim 3 , wherein said agent is mazindol. 
     
     
         5 . The method of  claim 4 , wherein mazindol is administered in the amount of from 0.1 mg/day to 20 mg/day. 
     
     
         6 . The method of  claim 5 , wherein mazindol is administered in the amount of from 0.5 mg/day to 6 mg/day. 
     
     
         7 . The method of  claim 4 , wherein mazindol is administered from 1 to 3 times a day. 
     
     
         8 . The method of  claim 4 , wherein said disorder is an attention deficit hyperactivity disorder. 
     
     
         9 . A pharmaceutical composition for the treatment of central nervous system disorders comprising from 0.1 mg to 20 mg of mazindol and a pharmaceutical carrier.